These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23588841)

  • 1. Can we stop ordering prostate-specific antigen screening tests?
    Katz MH
    JAMA Intern Med; 2013 May; 173(10):847-8. PubMed ID: 23588841
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen testing in france.
    Braillon A
    JAMA Intern Med; 2013 Nov; 173(21):2014. PubMed ID: 24276059
    [No Abstract]   [Full Text] [Related]  

  • 3. Risks of PSA screening now better understood.
    Peres J
    J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
    [No Abstract]   [Full Text] [Related]  

  • 4. Why I will continue to screen prostate-specific antigen for myself and other appropriate men.
    Keller DL
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394929
    [No Abstract]   [Full Text] [Related]  

  • 5. Why I will continue to screen prostate-specific antigen for myself and other appropriate men--reply.
    Katz MH
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394931
    [No Abstract]   [Full Text] [Related]  

  • 6. States renewing attention to prostate cancer.
    Rossiter C
    NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022
    [No Abstract]   [Full Text] [Related]  

  • 7. Investigation momentum: the relentless pursuit to resolve uncertainty.
    Sah S; Elias P; Ariely D
    JAMA Intern Med; 2013 May; 173(10):932-3. PubMed ID: 23588200
    [No Abstract]   [Full Text] [Related]  

  • 8. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 9. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancer screening gets risk-specific.
    Peres J
    J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing risk: does this patient have prostate cancer?
    Carter HB
    J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 13. The cautionary tale of PSA testing.
    Hoffman RM; Zeliadt SB
    Arch Intern Med; 2010 Jul; 170(14):1262-3. PubMed ID: 20660847
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 15. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 16. [Systematic PSA screening has been tried in Region Skåne. Balanced information gives chance for equal treatment according to a pilot project].
    Bratt O; Lundgren R; Ahlgren G
    Lakartidningen; 2012 Sep 12-18; 109(37):1610-2. PubMed ID: 23077769
    [No Abstract]   [Full Text] [Related]  

  • 17. PSA screening isn’t “nonsense”—it saved my life.
    Orwig S
    J Fam Pract; 2011 Aug; 60(8):453. PubMed ID: 21928548
    [No Abstract]   [Full Text] [Related]  

  • 18. PSA screening: the bottom line.
    Elhilali MM
    CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 20. Study supports PSA velocity risk count.
    Fillon M
    J Natl Cancer Inst; 2012 Jul; 104(14):1042-3. PubMed ID: 22781432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.